HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.